| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/17/2003 | US20030073608 Alzheimer's disease; administering neurotransmitter antagonist |
| 04/17/2003 | US20030073218 Enzyme inhibitor for us in the treatment and prevention of tumors |
| 04/17/2003 | US20030073167 DNA encoding SNORF36 receptors |
| 04/17/2003 | US20030073123 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition |
| 04/17/2003 | US20030073118 MID 9002, a human sulfatase family member and uses therefor |
| 04/17/2003 | US20030073080 Genetically engineered viral nucleotide sequences for use as tool in gene therapy and vaccine development |
| 04/17/2003 | US20030073076 Analyzing modulators or treatments of fibroproliferative diseases; obtain sample, incubate with modulator, monitor marker expression, decreased expression indicate effective modulator |
| 04/17/2003 | US20030072825 Intratumoral use of dinitrochorobenzene: composition and use of injections including particular applications |
| 04/17/2003 | US20030072822 Methods for treating disorders using plant extracts |
| 04/17/2003 | US20030072819 Compositions and methods for enhancing drug delivery |
| 04/17/2003 | US20030072806 Antifungal formulation for therapy of fungal infection of the skin |
| 04/17/2003 | US20030072804 Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| 04/17/2003 | US20030072800 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 04/17/2003 | US20030072785 Mixtures for stimulating glucose up-take |
| 04/17/2003 | US20030072783 Administering nitric oxide adduct to a damaged vascular surface, wherein damaged vascular surface is interior surface of a blood vessel in which damage to endothelium or subendothelium, narrowing or stenosis of vessel has occured |
| 04/17/2003 | US20030072767 Compositions and methods for WT1 specific immunotherapy |
| 04/17/2003 | US20030072760 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 04/17/2003 | US20030072756 Combination therapy using an IL-1 inhibitor and methotrexate |
| 04/17/2003 | US20030072752 Two novel genes from psoriatic epidermis: psoriastatin type i and psoriastatin type ii |
| 04/17/2003 | US20030072749 Applying at least one chondroitin sulfate proteoglycan-degrading enzyme to the damaged nerve for promoting repair of a damaged nerve |
| 04/17/2003 | US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 04/17/2003 | US20030072736 Human tumor necrosis factor receptor TR16 |
| 04/17/2003 | US20030072732 Comprises association between elastase inhibitor compound of the N-acylaminoamide family and at least one antiinflammatory compound; for improving skin ageing and/or photoageing signs by slowing down connective tissue alterations |
| 04/17/2003 | US20030072718 Spray drying to produce stable, high-potency dry powder formulations; utility in pulmonary delivery of interferons |
| 04/17/2003 | US20030070621 Apparatus and method for producing a foam bovine teat dip |
| 04/17/2003 | CA2473970A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 04/17/2003 | CA2471968A1 Immunostimulatory nucleic acids and use thereof |
| 04/17/2003 | CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | CA2462913A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 04/17/2003 | CA2462876A1 Compositions for and methods of treating and preventing sirs/sepsis |
| 04/17/2003 | CA2462875A1 Allylamides useful in the treatment of alzheimer's disease |
| 04/17/2003 | CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | CA2462861A1 Piperidine compounds as muscarinic antagonists |
| 04/17/2003 | CA2462582A1 Adjuvants for nucleic acid vaccines |
| 04/17/2003 | CA2462291A1 Methods and compositions for treating dermal lesions |
| 04/17/2003 | CA2462272A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| 04/17/2003 | CA2462185A1 Methods for modulating activity of the fxr nuclear receptor |
| 04/17/2003 | CA2461900A1 Leukocyte inactivation module |
| 04/17/2003 | CA2461655A1 Nogo receptor-mediated blockade of axonal growth |
| 04/17/2003 | CA2461435A1 Angiopoietin-2 specific binding agents |
| 04/17/2003 | CA2461092A1 Pharmaceutical composition for the treatment of disorders of non-human mammals |
| 04/17/2003 | CA2461064A1 Inhibition of stat-1 |
| 04/17/2003 | CA2460625A1 Structural and cytoskeleton-associated proteins |
| 04/17/2003 | CA2460480A1 Molecules for disease detection and treatment |
| 04/17/2003 | CA2460476A1 Protein modification and maintenance molecules |
| 04/17/2003 | CA2458645A1 Intracellular signaling molecules |
| 04/17/2003 | CA2458392A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 04/16/2003 | EP1302541A1 Receptor protein specifically recognizing bacterial dna |
| 04/16/2003 | EP1302472A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 04/16/2003 | EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| 04/16/2003 | EP1302201A1 Pharmaceutical composition improved in peroral absorbability |
| 04/16/2003 | EP1301797A2 Antimicrobial agent |
| 04/16/2003 | EP1301611A2 Human rrp sequences and methods of use |
| 04/16/2003 | EP1301604A2 Substrates and assays for beta-secretase activity |
| 04/16/2003 | EP1301602A2 Fh-binding protein of streptococcus pneumoniae |
| 04/16/2003 | EP1301598A2 Cell cycle proteins and mitosis-associated molecules |
| 04/16/2003 | EP1301597A2 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 04/16/2003 | EP1301595A2 G-protein coupled receptors |
| 04/16/2003 | EP1301593A2 ANTISENSE COMPOSITIONS TARGETED TO $g(b) 1? ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 04/16/2003 | EP1301539A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 04/16/2003 | EP1301535A2 G-protein coupled receptors |
| 04/16/2003 | EP1301531A2 Reagents and methods for identification of binding agents |
| 04/16/2003 | EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301518A1 Tricyclic compounds as mrp1-inhibitors |
| 04/16/2003 | EP1301506A1 Cyclic amino acid derivatives |
| 04/16/2003 | EP1301500A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 04/16/2003 | EP1301486A2 Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301476A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 04/16/2003 | EP1301472A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 04/16/2003 | EP1301215A1 Radioactive compositions and methods of use thereof |
| 04/16/2003 | EP1301213A2 Multi-component biological transport systems |
| 04/16/2003 | EP1301209A1 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 04/16/2003 | EP1301201A1 Treatment of glycogen storage disease type ii |
| 04/16/2003 | EP1301196A2 Stimulation of bone growth with thrombin peptide derivatives |
| 04/16/2003 | EP1301182A2 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 04/16/2003 | EP1301171A1 Use of extracted soluble protein fractions |
| 04/16/2003 | EP1301076A2 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 04/16/2003 | EP1301074A2 Uses for nad synthetase inhibitors |
| 04/16/2003 | EP1056449B1 20-hete antagonists and agonists |
| 04/16/2003 | EP0942753B1 Combinations for use in increasing the potency of a substrate for multidrug resistance related protein |
| 04/16/2003 | EP0921810B1 Reduction of the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity |
| 04/16/2003 | EP0918455B1 Use of galanin to repair nerve damage |
| 04/16/2003 | EP0801554B1 Formulations and methods for reducing skin irritation |
| 04/16/2003 | EP0792154B1 Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna) |
| 04/16/2003 | EP0737069B1 Deuterised active agents in transdermal application |
| 04/16/2003 | EP0680338B1 Ganglioside-klh conjugate vaccines with qs-21 |
| 04/16/2003 | CN1411556A Synergistic activation of regulatory elements by Rel proteins and steroid receptor |
| 04/16/2003 | CN1411508A Oligonucleotides modulating expression of enzymes involved in synthesis of melanic pigments |
| 04/16/2003 | CN1411467A Compounds and use thereof to modify transport across cell membranes |
| 04/16/2003 | CN1411447A Polymorphic crystalline forms of celecoxib |
| 04/16/2003 | CN1411435A Novel use of phenyl hetero alkylamine derivatives |
| 04/16/2003 | CN1411386A Treatment of subnormal bone mineral density |
| 04/16/2003 | CN1411380A Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
| 04/16/2003 | CN1411376A Novel helicobacter pylori-binding substances and use thereof |
| 04/16/2003 | CN1411337A Anthelmintic compositions |
| 04/16/2003 | CN1410059A Treating method and medicine kit containing somatotrophic hormone secretory agent |
| 04/16/2003 | CN1105576C Insulin analog formulation |
| 04/16/2003 | CN1105573C Pharmaceutical composition |
| 04/16/2003 | CA2407771A1 Mixtures for stimulating glucose up-take |
| 04/15/2003 | US6548569 Biodegradable polyhydroxyalkanoate; orthopedics, surgery |